Treatment with alpinetin attenuated the neuroinflammatory cascade by reducing MPO activity, a marker of neutrophil infiltration, and suppressing glial activation in both microglia and astrocytes, which are key contributors to secondary injury following ischemia. Here, MPO is linked to ischemia.